The 4 linked references in paper Olga Shakhmatova O., О. Шахматова О. (2018) “СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ ДАБИГАТРАНА ИДАРУЦИЗУМАБ: ЧТО ИЗВЕСТНО НА СЕГОДНЯШНИЙ ДЕНЬ // IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE” / spz:neicon:aterotromboz:y:2018:i:2:p:147-157

  1. Alonso A., Bengtson L.G., MacLehose R.F., et al. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke. 2014 Aug; 45(8): 2286-91. doi: 10.1161/ STROKeAHA.114.006016. epub 2014 Jul 3.
  2. Giannandrea D., Caponi C., Mengoni A., et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J. Neurol. Neurosurg. Psychiatry. 2018; 0: 1–5. doi:10.1136/jnnp-2018-318658.
  3. Шахматова О.О. Специфические антидоты к новым пероральным антикоагулянтам. Атеротромбоз. 2016; 1: 81-94. [Shakhmatova OO. Specific reversal agents for new oral anticoagulants. Aterotromboz. 2016; 1: 81-94.] (In Russ).
  4. Kirchhof P., Benussi S., Kotecha D., et al. 2016 eSC Guidelines for the management of atrial fibrillation developed in collaboration with eACTS. European Heart Journal. 2016; 37(38): 2893–2962. https://doi. org/10.1093/eurheartj/ehw210.